Human Milk Oligosaccharides (HMO) Market-Global Industry Analysis and Forecast (2022-2029)


Human Milk Oligosaccharides (HMO) Market size is expected to reach nearly US$ 133.4 Mn by 2029 with the CAGR of 14.6% during the forecast period.

High Cost of Product Due to Expensive Manufacturing Process:

The low availability of a group of donors, and HMO cannot be produced directly from human milk are the key restraints for the growth of the human milk oligosaccharides (HMO) market. Now, producers are emerging technologies through chemical and enzymatic synthesis to generate human milk oligosaccharides (HMO). These synthetic and enzymatic methods need a high amount of capital and energy, but the production of the final product is comparatively low. For example, for costly substrates like glycosyltransferases, enzymatic synthesis is required and this is one of the main factors due to the high price of oligosaccharides of human milk.

Global Human Milk Oligosaccharides (HMO) MarketTo know about the Research Methodology :- Request Free Sample Report

Human Milk Oligosaccharides (HMO) Market Opportunities:

The growing concerns among consumers about gut health and the consumption of dietary supplements is expected to generate significant opportunities for the HMO Market. For instance, DuPont Nutrition & Health's CARE4U is used as a dietary supplement ingredient. The market viewing strong competition because of the increasing number of market entrants. Human milk oligosaccharides (HMOs) act as prebiotics in the human body and support to maintain gut health. They encourage bacterial growth, particularly bifidobacteria genus, in the gut, which helps improve metabolic activity.

Covid-19 Impact on the Human Milk Oligosaccharides (HMO) Market:

• The Covid-19 impact on the market like food production and delivery systems can be disrupted. Recent challenges in food like human milk oligosaccharides (HMO) supply-chain, there is now significant concern about human milk oligosaccharides (HMO) production, processing, distribution, and demand.
• COVID-19 resulted in the movement restrictions of workers, fluctuations in demand of consumers, closure of food production facilities, restricted food trade policies, and financial pressures in the food supply chain. Facilities should change the working conditions and maintain the health and safety of employees by altering safety measures. Food companies face several challenges due to a drop in income, while others are working hard to meet the growing demand of retailers.

Human Milk Oligosaccharides (HMO) Market Segment Analysis


By Product, Lacto-N-neotetraose segment accounted for the largest market share in 2021

Lacto-N-neotetraose segment accounted for the largest market share of the global market in 2021. This is mainly due to the increasing growth of useful bifidobacteria and decreasing the growth of pathogenic bacteria which is ultimately appealing to the producers of food & beverages and food supplements. But, 2'-Fucosyllactose (2'FL) segment is expected to hold the highest CAGR of 14.6% during the forecast period (2022-2029). Producers of dietary supplements are shifting towards 2’-fucosyllactose (2’FL) because of its capability of changing the composition and activity of gut microbiota from formula-fed infants receiving complementary feeding and its support the development of a healthy gut, which is likely to push the growth of the human milk oligosaccharides (HMO) market.

By Application, Infant Formulas application accounted for the largest market share in 2021

Infant Formulas application accounted for the largest market share in 2021 and is expected to hold steady dominance in the forecasted period (2022-2029). This is mainly due to the growing middle-class family unit and the numerous working women are the key factors increasing the demand for human milk oligosaccharides (HMOs) in infant formulas. Likewise, the demand for human milk oligosaccharides (HMOs) in infant formulas is increasing as it encourages infant health by supporting digestive, immune, and intellectual improvement.

Global Human Milk Oligosaccharides (HMO) Market Regional Insights:

Europe is expected to account for the largest market during the forecast period in terms of value. Europe is the key region dominating the human milk oligosaccharides (HMO) market with a revenue share of 42.15% in 2021. This is mainly because of the occurrence of various prominent infant formula and baby food producers with technological advancement. The country in Europe like the UK has recorded the lowest rate for breastfeeding. This is mainly because of the increasing rate of working women population and cuts in public health funding.

Asia Pacific region is expected to be the fastest growing region with highest CAGR of 14.6% during the forecast period.

Asia Pacific region is expected to be the fastest-growing region with the highest CAGR of 14.6% during the forecast period 2022-2029. This is mainly because of the rising population, mortality rate, disposable income, and consumer alertness about health and hygiene. Growing concerns regarding gut diseases, high blood pressure, and diabetes. The developing economies such as China and India are the emerging markets for baby foods and dietary supplements.

The objective of the report is to provide the following:

• To provide market size, forecast data for global, regional and market segments
• To provide strategic developments, benchmarking and market share analysis of 10 players operating in the global human milk oligosaccharides (HMOs) market
• Detailed insights on drivers, restraints, opportunities, and challenges in the human milk oligosaccharides (HMOs) industry
• Impact of technological advancements in the human milk oligosaccharides (HMOs) market and its future outlook
• High level insights on the regional and country level analysis along with regional attractiveness
• Market intelligence on the growth trends and opportunity analysis in the human milk oligosaccharides (HMOs) market at the segmental and overall market levels
• In-depth coverage of SWOT, PORTER, PEST and VALUE & SUPPLY CHAIN

• Demand Side Drivers:

o Increasing concerns among consumers regarding gut health including bacteria, archaea and fungi are the key drivers resulting market to reach USD xx Mn globally by 2029.
o Europe dominated the Human Milk Oligosaccharides (HMO) Market with a share of 42.18% in the year 2021.

• Supply Side Drivers:

o The market is driven by large players meeting 14.6% of the demand, which include manufacturers, supplier, and distributors. These players are pushing multiple offerings at different price points.
o Dutch multinational corporation (DSM) would acquire Glycom for $830 million, a Danish company, one of the leading supplier of human milk oligosaccharides (HMOs). With the acquisition, DSM will follow firms like BASF and DuPont, to expand its business presence in the next 5 years.
o According to DSM, the global HMO market is currently around US$ 110 million per year and growing rapidly. Glycom reported $80 million in sales in 2021, mostly to Nestlé, which is a large investor in Glycom.

Drivers: Growing consumption of dietary supplements, encourage optimal health and help to prevent certain diseases, help to improve the brain development and enhance memory power, the demand of HMO in infant formula, market players are increasingly investing in the R&D activities, and among others are the key factors resulting the market to grow at a CAGR of 24.1% by 2029.

Rising Demand for HMO in Infant Formula:

The human milk oligosaccharides (HMO) market is poised to receive an upsurge because of useful properties like infection prevention, brain development and memory enhancement in humans, prebiotic effects, and improvement of intestinal health, the demand for HMOs in the design of infant formulas is growing. For instance, in June 2018, Abbott announced its new infant formula product, Similac Eye-Q Plus with human milk oligosaccharides (HMO), in Vietnam.

The addition of HMOs in functional food & beverage products supports the growth of good bacteria and can also eliminate harmful bacteria such as salmonella and campylobacter. The fast-rising health awareness among people in emerging countries like China and India is expected to boost market growth during the forecast period (2022-2029). For instance, in April 2021, Nestle S.A., presented three new products in the U.K., specifically, SMA Advanced Follow-on Formula, SMA Advanced Growing up Milk, and SMA Advanced Infant Formula. These products contained artificial HMOs and were planned for infants who were not breastfed. Such growths within the infant formula sector are expected to drive the demand for human milk oligosaccharides (HMO) in the current future.

Restraint: Lack of technology for large-scale production, high R&D cost, limited production, and stringent government regulations are likely to restrain the HMO market growth.

Scope of the Global Human Milk Oligosaccharides (HMO) Market: Inquire before buying






Global Human Milk Oligosaccharides (HMO) Market




Report Coverage
Details




Base Year:
2021
Forecast Period:
2022-2029




Historical Data:
2017 to 2021
Market Size in 2021:
US $ 44.8 Bn.




Forecast Period 2022 to 2029 CAGR:
14.6%
Market Size in 2029:
US $ 133.4 Bn.




 Segments Covered:
by Product
• Lacto-N-neotetraose (LNnT)
• Lacto-N-tetraose (LNT)
• 2'-Fucosyllactose (2'FL)
• 3'-Fucosyllactose (3'FL)
• 3'-Sialyllactose (3'SL)
• 6'-Sialyllactose (6'SL)
• Others




by Type
• Neutral
• Acidic




by Application
• Food & beverages
• Food supplements
• Infant formulas
• Others






 Human Milk Oligosaccharides (HMO) Market, By Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Holland, Turkey, Russia and Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, New Zealand, Australia, ASEAN and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina, Columbia and Rest of South America)

Key players operating in the Global Human Milk Oligosaccharides (HMO) Market

• Elicityl SA
• Medolac Laboratories
• Inbiose
• Glycosyn
• ZuChem
• Jennewein Biotechnologie
• Glycom
• Abbott
• BASF S.E
• Dupont De Nemours Inc
• Royal FrieslandCampina N.V
• Others

Frequently Asked Questions:

1. Which region has the largest share in Global Human Milk Oligosaccharides (HMO) Market?
Ans: North America region held the highest share in 2021.

2. What is the growth rate of Global Human Milk Oligosaccharides (HMO) Market?
Ans: The Global Human Milk Oligosaccharides (HMO) Market is expected to grow at a CAGR of 14.6% during forecast period 2022-2029.

3. What is scope of the Global Human Milk Oligosaccharides (HMO) Market report?
Ans:  The Global Human Milk Oligosaccharides (HMO) Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. What is the study period of this market?
Ans: The Global Human Milk Oligosaccharides (HMO) Market is studied from 2021 to 2029. 




Global Human Milk Oligosaccharides (HMO) Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Forms
2.3.2. Primary Research
2.3.2.1. Data from Primary Forms
2.3.2.2. Breakdown of Primary Forms

3. Executive Summary: Global Human Milk Oligosaccharides (HMO) Market Size, by Market Value (US$ Bn)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies

5. Supply Side and Demand Side Indicators

6. Global Human Milk Oligosaccharides (HMO) Market Analysis and Forecast
6.1. Human Milk Oligosaccharides (HMO) Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Human Milk Oligosaccharides (HMO) Market Analysis and Forecast, By Application
7.1. Introduction and Definition
7.2. Key Findings
7.3. Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Application
7.4. Human Milk Oligosaccharides (HMO) Market Size (US$ Bn) Forecast, By Application
7.5. Human Milk Oligosaccharides (HMO) Market Analysis, By Application
7.6. Human Milk Oligosaccharides (HMO) Market Attractiveness Analysis, By Application

8. Global Human Milk Oligosaccharides (HMO) Market Analysis and Forecast, By Product
8.1. Introduction and Definition
8.2. Key Findings
8.3. Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Product
8.4. Human Milk Oligosaccharides (HMO) Market Size (US$ Bn) Forecast, By Product
8.5. Human Milk Oligosaccharides (HMO) Market Analysis, By Product
8.6. Human Milk Oligosaccharides (HMO) Market Attractiveness Analysis, By Product

9. Global Human Milk Oligosaccharides (HMO) Market Analysis and Forecast, By Type
9.1. Introduction and Definition
9.2. Key Findings
9.3. Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Type
9.4. Human Milk Oligosaccharides (HMO) Market Size (US$ Bn) Forecast, By Type
9.5. Human Milk Oligosaccharides (HMO) Market Analysis, By Type
9.6. Human Milk Oligosaccharides (HMO) Market Attractiveness Analysis, By Type

10. Global Human Milk Oligosaccharides (HMO) Market Analysis, by Region
10.1. Human Milk Oligosaccharides (HMO) Market Value Share Analysis, by Region
10.2. Human Milk Oligosaccharides (HMO) Market Size (US$ Bn) Forecast, by Region
10.3. Human Milk Oligosaccharides (HMO) Market Attractiveness Analysis, by Region

11. North America Human Milk Oligosaccharides (HMO) Market Analysis
11.1. Key Findings
11.2. North America Human Milk Oligosaccharides (HMO) Market Overview
11.3. North America Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Application
11.4. North America Human Milk Oligosaccharides (HMO) Market Forecast, By Application
11.4.1. Food & beverages
11.4.2. Food supplements
11.4.3. Infant formulas
11.4.4. Others
11.5. North America Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Product
11.6. North America Human Milk Oligosaccharides (HMO) Market Forecast, By Product
11.6.1. Lacto-N-neotetraose (LNnT)
11.6.2. Lacto-N-tetraose (LNT)
11.6.3. 2'-Fucosyllactose (2'FL)
11.6.4. 3'-Fucosyllactose (3'FL)
11.6.5. 3'-Sialyllactose (3'SL)
11.6.6. 6'-Sialyllactose (6'SL)
11.6.7. Others
11.7. North America Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Type
11.8. North America Human Milk Oligosaccharides (HMO) Market Forecast, By Type
11.8.1. Neutral
11.8.2. Acidic
11.9. North America Human Milk Oligosaccharides (HMO) Market Value Share Analysis, by Country
11.10. North America Human Milk Oligosaccharides (HMO) Market Forecast, by Country
11.10.1. U.S.
11.10.2. Canada
11.11. North America Human Milk Oligosaccharides (HMO) Market Analysis, by Country
11.12. U.S. Human Milk Oligosaccharides (HMO) Market Forecast, By Application
11.12.1. Food & beverages
11.12.2. Food supplements
11.12.3. Infant formulas
11.12.4. Others
11.13. U.S. Human Milk Oligosaccharides (HMO) Market Forecast, By Product
11.13.1. Lacto-N-neotetraose (LNnT)
11.13.2. Lacto-N-tetraose (LNT)
11.13.3. 2'-Fucosyllactose (2'FL)
11.13.4. 3'-Fucosyllactose (3'FL)
11.13.5. 3'-Sialyllactose (3'SL)
11.13.6. 6'-Sialyllactose (6'SL)
11.13.7. Others
11.14. U.S. Human Milk Oligosaccharides (HMO) Market Forecast, By Type
11.14.1. Neutral
11.14.2. Acidic
11.15. Canada Human Milk Oligosaccharides (HMO) Market Forecast, By Application
11.15.1. Food & beverages
11.15.2. Food supplements
11.15.3. Infant formulas
11.15.4. Others
11.16. Canada Human Milk Oligosaccharides (HMO) Market Forecast, By Product
11.16.1. Lacto-N-neotetraose (LNnT)
11.16.2. Lacto-N-tetraose (LNT)
11.16.3. 2'-Fucosyllactose (2'FL)
11.16.4. 3'-Fucosyllactose (3'FL)
11.16.5. 3'-Sialyllactose (3'SL)
11.16.6. 6'-Sialyllactose (6'SL)
11.16.7. Others
11.17. Canada Human Milk Oligosaccharides (HMO) Market Forecast, By Type
11.17.1. Neutral
11.17.2. Acidic
11.18. North America Human Milk Oligosaccharides (HMO) Market Attractiveness Analysis
11.18.1. By Application
11.18.2. By Product
11.18.3. By Type
11.19. PEST Analysis
11.20. Key Trends
11.21. Key Developments

12. Europe Human Milk Oligosaccharides (HMO) Market Analysis
12.1. Key Findings
12.2. Europe Human Milk Oligosaccharides (HMO) Market Overview
12.3. Europe Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Application
12.4. Europe Human Milk Oligosaccharides (HMO) Market Forecast, By Application
12.4.1. Food & beverages
12.4.2. Food supplements
12.4.3. Infant formulas
12.4.4. Others
12.5. Europe Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Product
12.6. Europe Human Milk Oligosaccharides (HMO) Market Forecast, By Product
12.6.1. Lacto-N-neotetraose (LNnT)
12.6.2. Lacto-N-tetraose (LNT)
12.6.3. 2'-Fucosyllactose (2'FL)
12.6.4. 3'-Fucosyllactose (3'FL)
12.6.5. 3'-Sialyllactose (3'SL)
12.6.6. 6'-Sialyllactose (6'SL)
12.6.7. Others
12.7. Europe Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Type
12.8. Europe Human Milk Oligosaccharides (HMO) Market Forecast, By Type
12.8.1. Neutral
12.8.2. Acidic
12.9. Europe Human Milk Oligosaccharides (HMO) Market Value Share Analysis, by Country
12.10. Europe Human Milk Oligosaccharides (HMO) Market Forecast, by Country
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Norway
12.10.7. Russia
12.11. Europe Human Milk Oligosaccharides (HMO) Market Analysis, by Country
12.12. Germany Human Milk Oligosaccharides (HMO) Market Forecast, By Application
12.12.1. Food & beverages
12.12.2. Food supplements
12.12.3. Infant formulas
12.12.4. Others
12.13. Germany Human Milk Oligosaccharides (HMO) Market Forecast, By Product
12.13.1. Lacto-N-neotetraose (LNnT)
12.13.2. Lacto-N-tetraose (LNT)
12.13.3. 2'-Fucosyllactose (2'FL)
12.13.4. 3'-Fucosyllactose (3'FL)
12.13.5. 3'-Sialyllactose (3'SL)
12.13.6. 6'-Sialyllactose (6'SL)
12.13.7. Others
12.14. Germany Human Milk Oligosaccharides (HMO) Market Forecast, By Type
12.14.1. Neutral
12.14.2. Acidic
12.15. U.K. Human Milk Oligosaccharides (HMO) Market Forecast, By Application
12.15.1. Food & beverages
12.15.2. Food supplements
12.15.3. Infant formulas
12.15.4. Others
12.16. U.K. Human Milk Oligosaccharides (HMO) Market Forecast, By Product
12.16.1. Lacto-N-neotetraose (LNnT)
12.16.2. Lacto-N-tetraose (LNT)
12.16.3. 2'-Fucosyllactose (2'FL)
12.16.4. 3'-Fucosyllactose (3'FL)
12.16.5. 3'-Sialyllactose (3'SL)
12.16.6. 6'-Sialyllactose (6'SL)
12.16.7. Others
12.17. U.K. Human Milk Oligosaccharides (HMO) Market Forecast, By Type
12.17.1. Neutral
12.17.2. Acidic
12.18. France Human Milk Oligosaccharides (HMO) Market Forecast, By Application
12.18.1. Food & beverages
12.18.2. Food supplements
12.18.3. Infant formulas
12.18.4. Others
12.19. France Human Milk Oligosaccharides (HMO) Market Forecast, By Product
12.19.1. Lacto-N-neotetraose (LNnT)
12.19.2. Lacto-N-tetraose (LNT)
12.19.3. 2'-Fucosyllactose (2'FL)
12.19.4. 3'-Fucosyllactose (3'FL)
12.19.5. 3'-Sialyllactose (3'SL)
12.19.6. 6'-Sialyllactose (6'SL)
12.19.7. Others
12.20. France Human Milk Oligosaccharides (HMO) Market Forecast, By Type
12.20.1. Neutral
12.20.2. Acidic
12.21. Italy Human Milk Oligosaccharides (HMO) Market Forecast, By Application
12.21.1. Food & beverages
12.21.2. Food supplements
12.21.3. Infant formulas
12.21.4. Others
12.22. Italy Human Milk Oligosaccharides (HMO) Market Forecast, By Product
12.22.1. Lacto-N-neotetraose (LNnT)
12.22.2. Lacto-N-tetraose (LNT)
12.22.3. 2'-Fucosyllactose (2'FL)
12.22.4. 3'-Fucosyllactose (3'FL)
12.22.5. 3'-Sialyllactose (3'SL)
12.22.6. 6'-Sialyllactose (6'SL)
12.22.7. Others
12.23. Italy Human Milk Oligosaccharides (HMO) Market Forecast, By Type
12.23.1. Neutral
12.23.2. Acidic
12.24. Spain Human Milk Oligosaccharides (HMO) Market Forecast, By Application
12.24.1. Food & beverages
12.24.2. Food supplements
12.24.3. Infant formulas
12.24.4. Others
12.25. Spain Human Milk Oligosaccharides (HMO) Market Forecast, By Product
12.25.1. Lacto-N-neotetraose (LNnT)
12.25.2. Lacto-N-tetraose (LNT)
12.25.3. 2'-Fucosyllactose (2'FL)
12.25.4. 3'-Fucosyllactose (3'FL)
12.25.5. 3'-Sialyllactose (3'SL)
12.25.6. 6'-Sialyllactose (6'SL)
12.25.7. Others
12.26. Spain Human Milk Oligosaccharides (HMO) Market Forecast, By Type
12.26.1. Neutral
12.26.2. Acidic
12.27. Norway Human Milk Oligosaccharides (HMO) Market Forecast, By Application
12.27.1. Food & beverages
12.27.2. Food supplements
12.27.3. Infant formulas
12.27.4. Others
12.28. Norway Human Milk Oligosaccharides (HMO) Market Forecast, By Product
12.28.1. Lacto-N-neotetraose (LNnT)
12.28.2. Lacto-N-tetraose (LNT)
12.28.3. 2'-Fucosyllactose (2'FL)
12.28.4. 3'-Fucosyllactose (3'FL)
12.28.5. 3'-Sialyllactose (3'SL)
12.28.6. 6'-Sialyllactose (6'SL)
12.28.7. Others
12.29. Norway Human Milk Oligosaccharides (HMO) Market Forecast, By Type
12.29.1. Neutral
12.29.2. Acidic
12.30. Russia Human Milk Oligosaccharides (HMO) Market Forecast, By Application
12.30.1. Food & beverages
12.30.2. Food supplements
12.30.3. Infant formulas
12.30.4. Others
12.31. Russia Human Milk Oligosaccharides (HMO) Market Forecast, By Product
12.31.1. Lacto-N-neotetraose (LNnT)
12.31.2. Lacto-N-tetraose (LNT)
12.31.3. 2'-Fucosyllactose (2'FL)
12.31.4. 3'-Fucosyllactose (3'FL)
12.31.5. 3'-Sialyllactose (3'SL)
12.31.6. 6'-Sialyllactose (6'SL)
12.31.7. Others
12.32. Russia Human Milk Oligosaccharides (HMO) Market Forecast, By Type
12.32.1. Neutral
12.32.2. Acidic
12.33. Europe Human Milk Oligosaccharides (HMO) Market Attractiveness Analysis
12.33.1. By Application
12.33.2. By Product
12.33.3. By Type
12.34. PEST Analysis
12.35. Key Trends
12.36. Key Developments

13. Asia Pacific Human Milk Oligosaccharides (HMO) Market Analysis
13.1. Key Findings
13.2. Asia Pacific Human Milk Oligosaccharides (HMO) Market Overview
13.3. Asia Pacific Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Application
13.4. Asia Pacific Human Milk Oligosaccharides (HMO) Market Forecast, By Application
13.4.1. Food & beverages
13.4.2. Food supplements
13.4.3. Infant formulas
13.4.4. Others
13.5. Asia Pacific Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Product
13.6. Asia Pacific Human Milk Oligosaccharides (HMO) Market Forecast, By Product
13.6.1. Lacto-N-neotetraose (LNnT)
13.6.2. Lacto-N-tetraose (LNT)
13.6.3. 2'-Fucosyllactose (2'FL)
13.6.4. 3'-Fucosyllactose (3'FL)
13.6.5. 3'-Sialyllactose (3'SL)
13.6.6. 6'-Sialyllactose (6'SL)
13.6.7. Others
13.7. Asia Pacific Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Type
13.8. Asia Pacific Human Milk Oligosaccharides (HMO) Market Forecast, By Type
13.8.1. Neutral
13.8.2. Acidic
13.9. Asia Pacific Human Milk Oligosaccharides (HMO) Market Value Share Analysis, by Country
13.10. Asia Pacific Human Milk Oligosaccharides (HMO) Market Forecast, by Country
13.10.1. China
13.10.2. India
13.10.3. Japan
13.10.4. South Korea
13.10.5. Australia
13.10.6. Malaysia
13.10.7. Indonesia
13.11. Asia Pacific Human Milk Oligosaccharides (HMO) Market Analysis, by Country
13.12. China Human Milk Oligosaccharides (HMO) Market Forecast, By Application
13.12.1. Food & beverages
13.12.2. Food supplements
13.12.3. Infant formulas
13.12.4. Others
13.13. China Human Milk Oligosaccharides (HMO) Market Forecast, By Product
13.13.1. Lacto-N-neotetraose (LNnT)
13.13.2. Lacto-N-tetraose (LNT)
13.13.3. 2'-Fucosyllactose (2'FL)
13.13.4. 3'-Fucosyllactose (3'FL)
13.13.5. 3'-Sialyllactose (3'SL)
13.13.6. 6'-Sialyllactose (6'SL)
13.13.7. Others
13.14. China Human Milk Oligosaccharides (HMO) Market Forecast, By Type
13.14.1. Neutral
13.14.2. Acidic
13.15. India Human Milk Oligosaccharides (HMO) Market Forecast, By Application
13.15.1. Food & beverages
13.15.2. Food supplements
13.15.3. Infant formulas
13.15.4. Others
13.16. India Human Milk Oligosaccharides (HMO) Market Forecast, By Product
13.16.1. Lacto-N-neotetraose (LNnT)
13.16.2. Lacto-N-tetraose (LNT)
13.16.3. 2'-Fucosyllactose (2'FL)
13.16.4. 3'-Fucosyllactose (3'FL)
13.16.5. 3'-Sialyllactose (3'SL)
13.16.6. 6'-Sialyllactose (6'SL)
13.16.7. Others
13.17. India Human Milk Oligosaccharides (HMO) Market Forecast, By Type
13.17.1. Neutral
13.17.2. Acidic
13.18. Japan Human Milk Oligosaccharides (HMO) Market Forecast, By Application
13.18.1. Food & beverages
13.18.2. Food supplements
13.18.3. Infant formulas
13.18.4. Others
13.19. Japan Human Milk Oligosaccharides (HMO) Market Forecast, By Product
13.19.1. Lacto-N-neotetraose (LNnT)
13.19.2. Lacto-N-tetraose (LNT)
13.19.3. 2'-Fucosyllactose (2'FL)
13.19.4. 3'-Fucosyllactose (3'FL)
13.19.5. 3'-Sialyllactose (3'SL)
13.19.6. 6'-Sialyllactose (6'SL)
13.19.7. Others
13.20. Japan Human Milk Oligosaccharides (HMO) Market Forecast, By Type
13.20.1. Neutral
13.20.2. Acidic
13.21. South Korea Human Milk Oligosaccharides (HMO) Market Forecast, By Application
13.21.1. Food & beverages
13.21.2. Food supplements
13.21.3. Infant formulas
13.21.4. Others
13.22. South Korea Human Milk Oligosaccharides (HMO) Market Forecast, By Product
13.22.1. Lacto-N-neotetraose (LNnT)
13.22.2. Lacto-N-tetraose (LNT)
13.22.3. 2'-Fucosyllactose (2'FL)
13.22.4. 3'-Fucosyllactose (3'FL)
13.22.5. 3'-Sialyllactose (3'SL)
13.22.6. 6'-Sialyllactose (6'SL)
13.22.7. Others
13.23. South Korea Human Milk Oligosaccharides (HMO) Market Forecast, By Type
13.23.1. Neutral
13.23.2. Acidic
13.24. Australia Human Milk Oligosaccharides (HMO) Market Forecast, By Application
13.24.1. Food & beverages
13.24.2. Food supplements
13.24.3. Infant formulas
13.24.4. Others
13.25. Australia Human Milk Oligosaccharides (HMO) Market Forecast, By Product
13.25.1. Lacto-N-neotetraose (LNnT)
13.25.2. Lacto-N-tetraose (LNT)
13.25.3. 2'-Fucosyllactose (2'FL)
13.25.4. 3'-Fucosyllactose (3'FL)
13.25.5. 3'-Sialyllactose (3'SL)
13.25.6. 6'-Sialyllactose (6'SL)
13.25.7. Others
13.26. Australia Human Milk Oligosaccharides (HMO) Market Forecast, By Type
13.26.1. Neutral
13.26.2. Acidic
13.27. Malaysia Human Milk Oligosaccharides (HMO) Market Forecast, By Application
13.27.1. Food & beverages
13.27.2. Food supplements
13.27.3. Infant formulas
13.27.4. Others
13.28. Malaysia Human Milk Oligosaccharides (HMO) Market Forecast, By Product
13.28.1. Lacto-N-neotetraose (LNnT)
13.28.2. Lacto-N-tetraose (LNT)
13.28.3. 2'-Fucosyllactose (2'FL)
13.28.4. 3'-Fucosyllactose (3'FL)
13.28.5. 3'-Sialyllactose (3'SL)
13.28.6. 6'-Sialyllactose (6'SL)
13.28.7. Others
13.29. Malaysia Human Milk Oligosaccharides (HMO) Market Forecast, By Type
13.29.1. Neutral
13.29.2. Acidic
13.30. Indonesia Human Milk Oligosaccharides (HMO) Market Forecast, By Application
13.30.1. Food & beverages
13.30.2. Food supplements
13.30.3. Infant formulas
13.30.4. Others
13.31. Indonesia Human Milk Oligosaccharides (HMO) Market Forecast, By Product
13.31.1. Lacto-N-neotetraose (LNnT)
13.31.2. Lacto-N-tetraose (LNT)
13.31.3. 2'-Fucosyllactose (2'FL)
13.31.4. 3'-Fucosyllactose (3'FL)
13.31.5. 3'-Sialyllactose (3'SL)
13.31.6. 6'-Sialyllactose (6'SL)
13.31.7. Others
13.32. Indonesia Human Milk Oligosaccharides (HMO) Market Forecast, By Type
13.32.1. Neutral
13.32.2. Acidic
13.33. Vietnam Human Milk Oligosaccharides (HMO) Market Forecast, By Application
13.33.1. Food & beverages
13.33.2. Food supplements
13.33.3. Infant formulas
13.33.4. Others
13.34. Vietnam Human Milk Oligosaccharides (HMO) Market Forecast, By Product
13.34.1. Lacto-N-neotetraose (LNnT)
13.34.2. Lacto-N-tetraose (LNT)
13.34.3. 2'-Fucosyllactose (2'FL)
13.34.4. 3'-Fucosyllactose (3'FL)
13.34.5. 3'-Sialyllactose (3'SL)
13.34.6. 6'-Sialyllactose (6'SL)
13.34.7. Others
13.35. Vietnam Human Milk Oligosaccharides (HMO) Market Forecast, By Type
13.35.1. Neutral
13.35.2. Acidic
13.36. Asia Pacific Human Milk Oligosaccharides (HMO) Market Attractiveness Analysis
13.36.1. By Application
13.36.2. By Product
13.36.3. By Type
13.37. PEST Analysis
13.38. Key Trends
13.39. Key Developments

14. Middle East & Africa Human Milk Oligosaccharides (HMO) Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Human Milk Oligosaccharides (HMO) Market Overview
14.3. Middle East & Africa Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Application
14.4. Middle East & Africa Human Milk Oligosaccharides (HMO) Market Forecast, By Application
14.4.1. Food & beverages
14.4.2. Food supplements
14.4.3. Infant formulas
14.4.4. Others
14.5. Middle East & Africa Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Product
14.6. Middle East & Africa Human Milk Oligosaccharides (HMO) Market Forecast, By Product
14.6.1. Lacto-N-neotetraose (LNnT)
14.6.2. Lacto-N-tetraose (LNT)
14.6.3. 2'-Fucosyllactose (2'FL)
14.6.4. 3'-Fucosyllactose (3'FL)
14.6.5. 3'-Sialyllactose (3'SL)
14.6.6. 6'-Sialyllactose (6'SL)
14.6.7. Others
14.7. Middle East & Africa Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Type
14.8. Middle East & Africa Human Milk Oligosaccharides (HMO) Market Forecast, By Type
14.8.1. Neutral
14.8.2. Acidic
14.9. Middle East & Africa Human Milk Oligosaccharides (HMO) Market Value Share Analysis, by Country
14.10. Middle East & Africa Human Milk Oligosaccharides (HMO) Market Forecast, by Country
14.10.1. GCC
14.10.2. South Africa
14.10.3. Nigeria
14.10.4. Egypt
14.11. Middle East & Africa Human Milk Oligosaccharides (HMO) Market Analysis, by Country
14.12. GCC Human Milk Oligosaccharides (HMO) Market Forecast, By Application
14.12.1. Food & beverages
14.12.2. Food supplements
14.12.3. Infant formulas
14.12.4. Others
14.13. GCC Human Milk Oligosaccharides (HMO) Market Forecast, By Product
14.13.1. Lacto-N-neotetraose (LNnT)
14.13.2. Lacto-N-tetraose (LNT)
14.13.3. 2'-Fucosyllactose (2'FL)
14.13.4. 3'-Fucosyllactose (3'FL)
14.13.5. 3'-Sialyllactose (3'SL)
14.13.6. 6'-Sialyllactose (6'SL)
14.13.7. Others
14.14. GCC Human Milk Oligosaccharides (HMO) Market Forecast, By Type
14.14.1. Neutral
14.14.2. Acidic
14.15. South Africa Human Milk Oligosaccharides (HMO) Market Forecast, By Application
14.15.1. Food & beverages
14.15.2. Food supplements
14.15.3. Infant formulas
14.15.4. Others
14.16. South Africa Human Milk Oligosaccharides (HMO) Market Forecast, By Product
14.16.1. Lacto-N-neotetraose (LNnT)
14.16.2. Lacto-N-tetraose (LNT)
14.16.3. 2'-Fucosyllactose (2'FL)
14.16.4. 3'-Fucosyllactose (3'FL)
14.16.5. 3'-Sialyllactose (3'SL)
14.16.6. 6'-Sialyllactose (6'SL)
14.16.7. Others
14.17. South Africa Human Milk Oligosaccharides (HMO) Market Forecast, By Type
14.17.1. Neutral
14.17.2. Acidic
14.18. Nigeria Human Milk Oligosaccharides (HMO) Market Forecast, By Application
14.18.1. Food & beverages
14.18.2. Food supplements
14.18.3. Infant formulas
14.18.4. Others
14.19. Nigeria Human Milk Oligosaccharides (HMO) Market Forecast, By Product
14.19.1. Lacto-N-neotetraose (LNnT)
14.19.2. Lacto-N-tetraose (LNT)
14.19.3. 2'-Fucosyllactose (2'FL)
14.19.4. 3'-Fucosyllactose (3'FL)
14.19.5. 3'-Sialyllactose (3'SL)
14.19.6. 6'-Sialyllactose (6'SL)
14.19.7. Others
14.20. Nigeria Human Milk Oligosaccharides (HMO) Market Forecast, By Type
14.20.1. Neutral
14.20.2. Acidic
14.21. Egypt Human Milk Oligosaccharides (HMO) Market Forecast, By Application
14.21.1. Food & beverages
14.21.2. Food supplements
14.21.3. Infant formulas
14.21.4. Others
14.22. Egypt Human Milk Oligosaccharides (HMO) Market Forecast, By Product
14.22.1. Lacto-N-neotetraose (LNnT)
14.22.2. Lacto-N-tetraose (LNT)
14.22.3. 2'-Fucosyllactose (2'FL)
14.22.4. 3'-Fucosyllactose (3'FL)
14.22.5. 3'-Sialyllactose (3'SL)
14.22.6. 6'-Sialyllactose (6'SL)
14.22.7. Others
14.23. Egypt Human Milk Oligosaccharides (HMO) Market Forecast, By Type
14.23.1. Neutral
14.23.2. Acidic
14.24. Middle East & Africa Human Milk Oligosaccharides (HMO) Market Attractiveness Analysis
14.24.1. By Application
14.24.2. By Product
14.24.3. By Type
14.25. PEST Analysis
14.26. Key Trends
14.27. Key Developments

15. South America Human Milk Oligosaccharides (HMO) Market Analysis
15.1. Key Findings
15.2. South America Human Milk Oligosaccharides (HMO) Market Overview
15.3. South America Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Application
15.4. South America Human Milk Oligosaccharides (HMO) Market Forecast, By Application
15.4.1. Food & beverages
15.4.2. Food supplements
15.4.3. Infant formulas
15.4.4. Others
15.5. South America Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Product
15.6. South America Human Milk Oligosaccharides (HMO) Market Forecast, By Product
15.6.1. Lacto-N-neotetraose (LNnT)
15.6.2. Lacto-N-tetraose (LNT)
15.6.3. 2'-Fucosyllactose (2'FL)
15.6.4. 3'-Fucosyllactose (3'FL)
15.6.5. 3'-Sialyllactose (3'SL)
15.6.6. 6'-Sialyllactose (6'SL)
15.6.7. Others
15.7. South America Human Milk Oligosaccharides (HMO) Market Value Share Analysis, By Type
15.8. South America Human Milk Oligosaccharides (HMO) Market Forecast, By Type
15.8.1. Neutral
15.8.2. Acidic
15.9. South America Human Milk Oligosaccharides (HMO) Market Value Share Analysis, by Country
15.10. South America Human Milk Oligosaccharides (HMO) Market Forecast, by Country
15.10.1. Brazil
15.10.2. Mexico
15.10.3. Argentina
15.11. South America Human Milk Oligosaccharides (HMO) Market Analysis, by Country
15.12. Brazil Human Milk Oligosaccharides (HMO) Market Forecast, By Application
15.12.1. Food & beverages
15.12.2. Food supplements
15.12.3. Infant formulas
15.12.4. Others
15.13. Brazil Human Milk Oligosaccharides (HMO) Market Forecast, By Product
15.13.1. Lacto-N-neotetraose (LNnT)
15.13.2. Lacto-N-tetraose (LNT)
15.13.3. 2'-Fucosyllactose (2'FL)
15.13.4. 3'-Fucosyllactose (3'FL)
15.13.5. 3'-Sialyllactose (3'SL)
15.13.6. 6'-Sialyllactose (6'SL)
15.13.7. Others
15.14. Brazil Human Milk Oligosaccharides (HMO) Market Forecast, By Type
15.14.1. Neutral
15.14.2. Acidic
15.15. Mexico Human Milk Oligosaccharides (HMO) Market Forecast, By Application
15.15.1. Food & beverages
15.15.2. Food supplements
15.15.3. Infant formulas
15.15.4. Others
15.16. Mexico Human Milk Oligosaccharides (HMO) Market Forecast, By Product
15.16.1. Lacto-N-neotetraose (LNnT)
15.16.2. Lacto-N-tetraose (LNT)
15.16.3. 2'-Fucosyllactose (2'FL)
15.16.4. 3'-Fucosyllactose (3'FL)
15.16.5. 3'-Sialyllactose (3'SL)
15.16.6. 6'-Sialyllactose (6'SL)
15.16.7. Others
15.17. Mexico Human Milk Oligosaccharides (HMO) Market Forecast, By Type
15.17.1. Neutral
15.17.2. Acidic
15.18. Argentina Human Milk Oligosaccharides (HMO) Market Forecast, By Application
15.18.1. Food & beverages
15.18.2. Food supplements
15.18.3. Infant formulas
15.18.4. Others
15.19. Argentina Human Milk Oligosaccharides (HMO) Market Forecast, By Product
15.19.1. Lacto-N-neotetraose (LNnT)
15.19.2. Lacto-N-tetraose (LNT)
15.19.3. 2'-Fucosyllactose (2'FL)
15.19.4. 3'-Fucosyllactose (3'FL)
15.19.5. 3'-Sialyllactose (3'SL)
15.19.6. 6'-Sialyllactose (6'SL)
15.19.7. Others
15.20. Argentina Human Milk Oligosaccharides (HMO) Market Forecast, By Type
15.20.1. Neutral
15.20.2. Acidic
15.21. South America Human Milk Oligosaccharides (HMO) Market Attractiveness Analysis
15.21.1. By Application
15.21.2. By Product
15.21.3. By Type
15.22. PEST Analysis
15.23. Key Trends
15.24. Key Developments

16. Company Profiles
16.1. Market Share Analysis, by Company
16.2. Competition Matrix

16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
16.2.2. New Product Launches and Product Enhancements
16.2.3. Market Consolidation
16.2.3.1. M&A by Regions, Investment and Applications
16.2.3.2. M&A Key Players, Forward Integration and Backward
Integration

16.3. Company Profiles: Key Players
16.3.1. Elicityl SA
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategy
16.3.1.5. Recent Developments
16.3.1.6. Development Footprint
16.3.2. Medolac Laboratories
16.3.3. Inbiose
16.3.4. Glycosyn
16.3.5. ZuChem
16.3.6. Jennewein Biotechnologie
16.3.7. Glycom
16.3.8. Abbott
16.3.9. BASF S.E
16.3.10. Dupont De Nemours Inc
16.3.11. Royal FrieslandCampina N.V
16.3.12. Others

17. Primary Key Insights
  • INQUIRE BEFORE BUYING